ARA-290 (cibinetide) is an investigational peptide that has completed several small, early-phase human trials but is not approved anywhere. This page describes what those trials measured — not established benefits.
Overview
ARA-290's studied benefit is specific: in three small randomized trials, it improved symptoms and nerve-fiber measures in people with small-fiber neuropathy — nerve damage affecting the thin fibers that carry pain and temperature signals. It is an 11-amino-acid peptide engineered from helix B of erythropoietin (EPO), designed to keep EPO's tissue-protective signaling while discarding its red-blood-cell effects. That is a real and unusual profile for a research peptide: actual placebo-controlled human data. It is equally real that the trials were small, short, and in specific disease populations — nothing about them demonstrates benefits for healthy people.
The human trial record, study by study
- Sarcoidosis small-fiber neuropathy (2012): 22 patients randomized to ARA-290 (2 mg IV three times weekly) or placebo for 4 weeks. The treated group's small-fiber neuropathy screening score improved significantly versus placebo (−11.5 vs −2.9), with gains in pain and quality-of-life measures and no safety concerns (Molecular Medicine 2012).
- Type 2 diabetes with painful neuropathy (2014): a 28-day double-blind phase 2 trial of 4 mg subcutaneous daily. Neuropathic symptoms on the PainDetect questionnaire improved significantly, and patients with reduced corneal nerve-fiber density at baseline showed regrowth on treatment (Molecular Medicine 2014).
- Sarcoidosis, dose-ranging (2017): 64 subjects randomized to cibinetide 1, 4, or 8 mg daily or placebo for 28 days. The 4 mg dose — interestingly, not the 8 mg — significantly increased corneal nerve-fiber area and regenerating skin nerve fibers; pain improved across all groups including placebo (Investigative Ophthalmology & Visual Science 2017).
Pattern worth noticing: the objective nerve-regrowth measures moved more convincingly than subjective pain scores, which showed large placebo responses.
The unexpected metabolic signal
The diabetes trial produced a finding beyond nerves: participants on ARA-290 showed improved hemoglobin A1c (long-term blood glucose) that persisted through the 56-day observation period, alongside cholesterol changes (Molecular Medicine 2014). This is a secondary finding from one 28-day study — hypothesis-generating, not a metabolic indication — but it is why ARA-290 occasionally appears in metabolic-health discussions.
Mechanism — tissue protection without the blood effects
EPO signals through two different receptor systems: the classical homodimeric EPO receptor that drives red-blood-cell production, and a tissue-protective complex — the "innate repair receptor," pairing the EPO receptor with the beta-common receptor (CD131) — that assembles locally in injured or inflamed tissue. ARA-290 was built to engage only the second. The design goal is anti-inflammatory, pro-repair signaling without raising hematocrit, and none of the trials above reported blood-count problems. This receptor selectivity is also why the corneal nerve-fiber findings matter scientifically: regrowing measurable nerve structure is a repair outcome, not just a symptom score, and it is the kind of endpoint the innate-repair-receptor hypothesis predicts.
What remains unproven
ARA-290 has never been tested in a large confirmatory trial, was never submitted for approval, and has no data in healthy people, in athletic recovery, or for general "anti-inflammatory" use — contexts where it is nonetheless marketed. Longest studied exposure: 28 days. The gap between "improved nerve-fiber counts in 64 sarcoidosis patients" and the claims made by peptide vendors is wide, and the research overview lays out exactly what fills it — and what doesn't.